Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug manufacturing

Moorfields Eye Hospital to close its specials manufacturing facility

Moorfields Eye Hospital NHS Foundation Trust has decided to close its specials manufacturing facility in London, its board announced on 27 January 2015.

Manufacturing of specials has been suspended at the plant since December 2013 following concerns raised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) about some of its practices and processes.

Since then Moorfields Pharmaceuticals has outsourced its specials production and the board has now decided that it would be uneconomic to return production to the site. The market for specials has shrunk – down by 28.6% since 2011 – at the same time that regulatory standards have become more rigorous, it says. Forty three staff are facing redundancy.

The company will continue its range of licensed medicines as well as its range of outsourced ophthalmic specials, which are not available from other suppliers.

Lucy Titcomb, lead ophthalmic pharmacist, Birmingham & Midland Eye Centre, says the announcement is disappointing as the unit was the only facility to deal with low usage, niche products.

“There are a few products previously made by Moorfields Pharmaceuticals for which we have no suitable alternative,” she says.

“Patients in whom intracameral cefuroxime, used as prophylaxis against endophthalmitis in cataract surgery, is contraindicated could be given moxifloxacin intracameral injection; patients with severe dry eye could use tretinoin eye drops and intraocular haemorrhage could be dispersed with intravitreal tissue plasminogen activator,” she adds.

“None of these are available from alternative sources and pharmacies supplying ophthalmic units will need to liaise with ophthalmic surgeons to discuss other options.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067721

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.